EUVIMEDEUVIMED entdecken
Open Access

A single-center experience of haploidentical stem cell transplantation in hematological malignancies

Ümit Yavuz Malkan, Hakan Göker, Haluk Demiroğlu, Fatma Tekin, Nadire Buket Akdemir, Elifcan Aladağ Karakulak, Nilgün Sayınalp, İbrahim Celalettin Haznedaroğlu, Osman İlhami Özcebe, Yahya Büyükaşık

Turkish Journal of Medical Sciences · 01.01.2023 · 53 (1) · 352-359

DOI: 10.55730/1300-0144.5591 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Turkish Journal of Medical Sciences, online erschienen am 01.01.2023. Verfasst von Ümit Yavuz Malkan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Faculty of Medicine, Hacettepe University, Ankara, Turkey. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Hematologic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/aim: Since well-designed prospective comparative trials are lacking, haploidentical hematopoietic stem cell transplantations approach should be based on the expertise of a particular center. In this study, we aimed to report the results and outcomes of patients who underwent haploidentical hematopoietic stem cell transplantation. Materials and methods: Thirty-nine patients who underwent transplantation in our clinic between 2015 and 2022 were retrospectively analyzed. Primary end point of this study is to find out the survival rates of the patients.

Results

The overall survival of patients was 29.9 ± 4.9 months. The disease-free survival of the patients was 37.8 ± 5.7 months. The 3-year overall survival rate of the patients was %50 and the 3-year disease-free survival rate of the patients was %53. Nineteen patients were nonsurvivors among a total of 39 patients. Busulfan-fludarabine-thiotepa was the most frequently used conditioning regimen for transplantation. Busulfan-fludarabin-antithymocyte globulin regimen is the second preferred conditioning regimen. Cyclosporine- cyclophosphamide-mycophenolate mofetil was the most widely used graft-versus-host disease prophylaxis regimen. Sixteen patients had graft-versus-host disease, 28% of the patients had acute graft-versus-host disease, and 13% had chronic graft-versus-host disease. Gastrointestinal system consists of the most involved organs in graft-versus-host disease since 15% of the patients had gastrointestinal graft-versus-host disease. First-degree relatives (parent/child) were the most frequent donor source for haploidentical hematopoietic stem cell transplantation. Sepsis was the most frequent reason of death among transplant patients.

Conclusion

In our center, we prefer to use high dose posttransplantation cyclophosphamide after haploidentical hematopoietic stem cell transplantation for graft-versus-host disease prophylaxis. With this approach, our center's overall survival and disease-free survival rates are comparable and compatible with the literature findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationGraft vs Host DiseaseHematologic NeoplasmsChildHumansBusulfanRetrospective StudiesProspective StudiesCyclophosphamideCyclosporineMycophenolic Acid

Stichwörter der Autor:innen

Graft-versus-host diseaseHaploidentical hematopoietic stem cell transplantationconditioning regimens

Substanzen

BusulfanCyclophosphamideCyclosporineMycophenolic Acid

Autor:innen und Institutionen

  • Department of Hematology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.

Zitieren

APA

Malkan, Ü. Y., Göker, H., Demiroğlu, H., Tekin, F., Akdemir, N. B., Karakulak, E. A., Sayınalp, N., Haznedaroğlu, İ. C., Özcebe, O. İ., & Büyükaşık, Y. (2023). A single-center experience of haploidentical stem cell transplantation in hematological malignancies. Turkish Journal of Medical Sciences, 53(1), 352-359. https://doi.org/10.55730/1300-0144.5591

Vancouver

Malkan ÜY, Göker H, Demiroğlu H, Tekin F, Akdemir NB, Karakulak EA, et al. A single-center experience of haploidentical stem cell transplantation in hematological malignancies. Turkish Journal of Medical Sciences. 2023;53(1):352-359. doi:10.55730/1300-0144.5591

BibTeX
@article{Malkan2023,
  author = {Malkan, Ümit Yavuz and Göker, Hakan and Demiroğlu, Haluk and Tekin, Fatma and Akdemir, Nadire Buket and Karakulak, Elifcan Aladağ and Sayınalp, Nilgün and Haznedaroğlu, İbrahim Celalettin and Özcebe, Osman İlhami and Büyükaşık, Yahya},
  title = {A single-center experience of haploidentical stem cell transplantation in hematological malignancies},
  journal = {Turkish Journal of Medical Sciences},
  year = {2023},
  volume = {53},
  number = {1},
  pages = {352--359},
  doi = {10.55730/1300-0144.5591}
}
Kostenlos starten →